Biotechnology News and Research

RSS

WPI to develop integrated monitoring system to reduce firefighter deaths and injuries

Worcester Polytechnic Institute (WPI) has received a one-year, $1 million award from the Federal Emergency Management Agency (FEMA) to develop the final component of an integrated monitoring system designed to reduce firefighter deaths and injuries by precisely locating and tracking them inside buildings in three dimensions, continuously monitoring their vital signs to warn incident commanders when they are at risk of stress-related heart attacks, and taking floor-to-ceiling temperature readings inside buildings to provide an early warning of impending flashover.

1 Dec 2009

Amgen to present updated data on Nplate at the 2009 ASH meeting

Amgen Inc. today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition (Dec. 5 - 8, 2009).

1 Dec 2009

Article on TYSABRI for treating patients with multiple sclerosis published

Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI- (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis.

1 Dec 2009

NRR to be available exclusively on OvidSP online search and discovery platform to all Ovid customers

As part of ongoing efforts to strengthen its presence in China's healthcare information market, Ovid, a part of Wolters Kluwer Health and a global leader in electronic scientific, medical, and academic information research solutions, is pleased to announce an agreement with Neural Regeneration Research (NRR), an English-language monthly journal dedicated to presenting peer-reviewed, evidence-based scholarly research in stem cells and regeneration.

1 Dec 2009

Patheon and JLL complete settlement agreement

The Special Committee of Independent Directors of Patheon Inc. ("Patheon" or the "Company") (TSX: PTI) and JLL Partners, Inc. and its affiliate, JLL Patheon Holdings, LLC (collectively, "JLL"), today announced that the Company and JLL have entered into a settlement agreement in respect of the pending legal actions between the parties.

1 Dec 2009

Biomagnetics Diagnostics announces Patent License Agreement with Los Alamos National Security

Biomagnetics Diagnostics Corp. (PINK SHEETS:BMGP), a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced the Company has finalized a "Patent License Agreement with Los Alamos National Security."

30 Nov 2009

Global CRO PRA International achieves Rave Accredited Plus status in the ASPire to Win program

Medidata Solutions, a leading global provider of hosted clinical development solutions, today announced that PRA International, a global clinical research organization (CRO), has achieved Rave Accredited Plus status in the ASPire to Win® program for CROs and other service providers.

30 Nov 2009

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Novavax, Inc. announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).

30 Nov 2009

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R).

30 Nov 2009

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

30 Nov 2009

$Stem cell technology for rapid healing of complicated bone fractures$

Stem cell technology for rapid healing of complicated bone fractures

A novel technology involving use of stem cells, developed by Hebrew University of Jerusalem researchers, has been applied to provide better and rapid healing for patients suffering from complicated bone fractures.

30 Nov 2009

WuXi PharmaTech recognized as 50 fastest-growing companies for the fifth consecutive year

WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company with operations in China and the United States, announced that it had been selected to the Deloitte Technology Fast 50 China 2009 list for the fifth consecutive year.

30 Nov 2009

Intellivest Securities Research publishes a Report on BioClinica

Intellivest Securities Research, Inc., ("ISR") a Georgia registered investment advisor, has published a Report on BioClinica, Inc. ( BIOC) which serves companies in the pharmaceutical, biotechnology and medical device industries.

30 Nov 2009

XenaCare Holdings becomes national sponsor of Arthritis Foundation

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.

27 Nov 2009

Kane Biotech increases current private placement offering from 3,846,154 units to 4,335,500 units

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, today announces that it has increased the current private placement offering (the "Offering"), first reported on November 16, 2009, from a maximum of 3,846,154 units to 4,335,500 Units, for total gross proceeds of up to $563,615.

27 Nov 2009

Cannasat Therapeutics reports net loss of $336,154 for the three months ended September 30, 2009

Cannasat Therapeutics Inc., a clinical stage pharmaceutical company developing products to treat neurological disorders, today announced its results for the nine months ended September 30, 2009. Unless specified otherwise, all amounts are in Canadian dollars.

27 Nov 2009

NCKU, ScinoPharm Taiwan sign MOU to establish university-industry cooperation

National Cheng Kung University (NCKU), Taiwan signed a MOU with ScinoPharm Taiwan Ltd. on Nov. 24th.

27 Nov 2009

International collaborative research projects to decipher the biology behind the ageing process

Research efforts to help the world's ageing population live longer healthier lives have been given a major boost with the announcement of six new transatlantic research projects aiming to understanding the biology of the ageing process.

26 Nov 2009

AMPAC Fine Chemicals receives Environmental Responsibility and Sustainability Award

AMPAC Fine Chemicals LLC (AFC), a subsidiary of American Pacific Corporation (Nasdaq: APFC) announced today that it received the Environmental Responsibility and Sustainability Award at the Annual Statewide Environmental Summit, sponsored by the California Manufacturers and Technology Association (CMTA), the Industrial Environmental Association (IEA) and the Chemical Industry Council of California (CICC) held in San Diego.

26 Nov 2009

Expanded HIV vaccine funding for biotechnology research crucial, says TAI

In honor of World AIDS Day, The AIDS Institute (TAI), one of the nation's leading advocacy organizations for support of people with HIV/AIDS and their providers, joined Nobel Laureate Dr. Francoise Barre-Sinoussi, in calling for government leaders, patient advocates and the research community to expand therapeutic HIV vaccine research.

26 Nov 2009

Biotechnology News and Research

WPI to develop integrated monitoring system to reduce firefighter deaths and injuries

Amgen to present updated data on Nplate at the 2009 ASH meeting

Article on TYSABRI for treating patients with multiple sclerosis published

NRR to be available exclusively on OvidSP online search and discovery platform to all Ovid customers

Patheon and JLL complete settlement agreement

Biomagnetics Diagnostics announces Patent License Agreement with Los Alamos National Security

Global CRO PRA International achieves Rave Accredited Plus status in the ASPire to Win program

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Stem cell technology for rapid healing of complicated bone fractures

WuXi PharmaTech recognized as 50 fastest-growing companies for the fifth consecutive year

Intellivest Securities Research publishes a Report on BioClinica

XenaCare Holdings becomes national sponsor of Arthritis Foundation

Kane Biotech increases current private placement offering from 3,846,154 units to 4,335,500 units

Cannasat Therapeutics reports net loss of $336,154 for the three months ended September 30, 2009

NCKU, ScinoPharm Taiwan sign MOU to establish university-industry cooperation

International collaborative research projects to decipher the biology behind the ageing process

AMPAC Fine Chemicals receives Environmental Responsibility and Sustainability Award

Expanded HIV vaccine funding for biotechnology research crucial, says TAI

Biotechnology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News